Neurology companies develop therapies, diagnostics and technologies that improve understanding and treatment of disorders affecting the brain, spinal cord and nervous system. The field addresses some of the most complex challenges in modern medicine.
This category includes companies working on:
Browse 114 UK neurology companies below.
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Molecular disease research spanning genetics, neurobiology and intracellular infections
Cambridge Institute for Medical Research is a University of Cambridge institute studying the molecular mechanisms of human disease. Researchers investigate protein folding, cellular quality control, membrane trafficking and organelle function, focusing on rare genetic disorders, neurological conditions and…
Biologic therapy for osteoarthritis pain
Levicept is a clinical-stage biotechnology company developing a once-monthly biologic treatment for osteoarthritis pain. Its receptor fusion protein is designed to rebalance neurotrophin signalling in affected joints, potentially providing a non-opioid treatment option. The company has completed a Phase II study…
Gene therapy biotech targeting neural circuit dysfunction
Sania Therapeutics is a biotechnology company developing genetic medicines for diseases caused by dysfunctional neural circuits. Its approach combines precision AAV delivery to selected neural circuits with tuneable neuromodulation, using human iPSC-derived neural models to direct the evolution of human-centric…
Targeted oral drug delivery platform for cancer, CNS and respiratory disease
TRX Biosciences is a biotechnology company developing a targeted oral drug delivery platform, enabling therapies to reach specific organs, cells and tissues for cancer, central nervous system, respiratory and immune system diseases. The company's technology is licensed to partner companies for use in their own drug…
Small molecule neuromodulators for neuropsychiatric disorders
Draig Therapeutics is a clinical-stage biotech developing small molecule drugs that modulate the glutamate and GABA neurotransmitter pathways to treat neuropsychiatric disorders. Its lead candidate DT-101 is an AMPA receptor positive allosteric modulator in Phase 2 development for major depressive disorder. The…
Gene therapy company targeting inherited and degenerative diseases
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and salivary gland disorders. The company operates end-to-end capabilities spanning viral vector design, GMP manufacturing, and clinical…
Regenerative cell therapy for sensorineural hearing loss
Rinri Therapeutics is a clinical-stage biotech developing allogeneic regenerative cell therapies for sensorineural hearing loss, a condition affecting over 400 million people worldwide for which no disease-modifying treatment currently exists. Its lead programme, Rincell-1, is an otic neural progenitor cell therapy…
Small molecule drugs targeting astrocytes in neurodegenerative disease
AstronauTx is a clinical-stage UK biotech developing oral small molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's approach targets astrocytes, brain support cells whose dysregulated inflammatory activity contributes to neurodegeneration, aiming to restore normal…
RNA-based therapeutics targeting neurodegenerative disease mechanisms
Harness Therapeutics is a Cambridge-based biotech developing oligonucleotide therapeutics that exploit post-transcriptional regulation to achieve controlled upregulation of disease-relevant proteins in the CNS. Its lead programme targets FAN1 nuclease in Huntington's disease to limit somatic DNA repeat expansion, with…
DUB inhibitor therapeutics targeting mitophagy and degenerative disease
Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by mitochondrial dysfunction. By targeting a mitochondria-localised DUB, the company's drug candidates are designed to enhance mitophagy, the cellular…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…
Precision small molecule drugs for obsessive-compulsive disorder
Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD). Its pipeline of three candidates targets distinct neurological mechanisms, including glutamate, AMPA, and dopamine pathways, with a biomarker-driven approach designed to match patients to…
Small molecule therapeutics targeting astrocytes in Parkinson's disease
Cellestial Health is a pre-clinical stage biotechnology company and University of Cambridge spinout developing small molecule therapeutics for Parkinson's disease and other neurodegenerative conditions. The company's approach targets astrocytic networks, a class of brain cells whose dysregulation contributes to…
Cambridge R&D hub for GPCR-based drug discovery
Nxera Pharma UK is the Cambridge-based drug discovery arm of Tokyo-listed Nxera Pharma, formerly Sosei Heptares, operating from Granta Park with approximately 170 scientists. Its structure-based drug discovery capabilities have produced over 50 resolved GPCR structures. Following a restructuring in November 2025, the…
Birthplace of molecular biology researching fundamental processes in human disease
The MRC Laboratory of Molecular Biology researches fundamental biological processes at the level of atoms, molecules, cells and organisms, applying this knowledge to major problems in human health and disease. The Laboratory pioneered techniques including DNA sequencing, protein structure determination and the…
Targeted small-molecule drugs for brain and metastatic cancers
Sentinel Oncology is a biotechnology company developing targeted small-molecule drugs for difficult-to-treat cancers. Its medicinal chemistry programmes investigate DNA damage responses and cell division. Some candidates are designed to cross the blood-brain barrier, targeting primary brain tumours and cancers that…
VNAR antibody shuttles for brain-targeted biologic therapies
Ossianix is a biopharmaceutical company developing single-domain VNAR antibody platforms for targeted delivery of therapeutics across the blood-brain barrier. Its TXP1 shuttle binds transferrin receptor 1 to transport antibody-based medicines into the central nervous system. The company engineers antibody fusions and…
Specialty biopharma with UK neurotoxin manufacturing hub
Ipsen is a French specialty biopharmaceutical company with one of three global hubs based in the UK. Its Wrexham site serves as the company's global neuroscience centre of excellence, responsible for research, development and manufacture of neurotoxin products including botulinum toxin. The London site houses…
Neuroimaging contract research organisation for clinical trial biomarker analysis
IXICO is a London-based imaging contract research organisation providing end-to-end neuroimaging services to biopharmaceutical companies conducting clinical trials in neurological diseases. The company collects, manages, and analyses MRI, PET, and SPECT imaging data from global trial sites, generating AI-driven…